De-risk your immuno-oncology drug development with HUB Organoids®

September 7, 2022

De-risk your immuno-oncology drug development with HUB Organoids®

Immunotherapy has shown substantial success in cancer treatment, however its efficacy is limited to only a subset of patients.

read more

Application of HUB Organoids® in immuno-oncology drug development

September 7, 2022

Application of HUB Organoids® in immuno-oncology drug development

Immuno-oncology (IO) therapy is a rapidly evolving treatment strategy to combat cancer

read more

HUB Toxicology Organoid Models

July 26, 2022

HUB Toxicology Organoid Models

Safety-related problems continue to be one of them major causes of drug attrition in preclinical and clinical development. Preclinical safety assessment is...

read more

License HUB Organoid Technology

June 3, 2022

License HUB Organoid Technology

HUB Organoid Technology represents a breakthrough in stem cell research and has allowed to gain better understanding in fields like organ development,...

read more

HUB Toxicology Organoid Models

February 17, 2022

HUB Toxicology Organoid Models

Safety-related problems continue to be one of the major causes of drug attrition in preclinical and clinical development. Preclinical safety assessment is...

read more

HUB Immuno-Oncology Organoid Models

February 17, 2022

HUB Immuno-Oncology Organoid Models

Advances in immunotherapy have revolutionized cancer treatment over the past few years – reflecting the importance of the interaction between the human...

read more

Cystic Fibrosis Organoid Models

February 17, 2022

Cystic Fibrosis Organoid Models

Cystic fibrosis (CF) is a genetic disease that is caused by mutations of the gene encoding for Cystic Fibrosis Transmembrane conductance Regulator...

read more

HUB tumor organoid models

February 17, 2022

HUB tumor organoid models

HUB Organoids™ are unique patient-derived in vitro models developed directly from patient biopsies or resections.

read more

X

Have any questions?

contact us